{"analyses":[{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.07","pValueComment":"The reported p-value is representative of the changes in levels of CD4+ cells/µL among all participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"NON_INFERIORITY","pValue":"0.13","pValueComment":"The reported p-value is representative of the changes in levels of CD4+cells/µL among all participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.15","pValueComment":"The reported p-value is representative of the changes in levels of CD4+cells/µL among all participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.03","pValueComment":"The reported p-value is representative of the changes in levels of CD4+cells/µL among HIV+ participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.06","pValueComment":"The reported p-value is representative of the changes in levels of CD4+cells/µL among HIV+ participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.79","pValueComment":"The reported p-value is representative of the changes in levels of CD4+cells/µL among HIV+ participants.","statisticalMethod":"Wilcoxon rank sum test"},{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.03","pValueComment":"The reported p-value is representative of the changes in levels of CD8+ cells/µL among all participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.008","pValueComment":"The reported p-value is representative of the changes in levels of CD8+ cells/µL among all participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.12","pValueComment":"The reported p-value is representative of the changes in levels of CD8+ cells/µL among all participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.02","pValueComment":"The reported p-value is representative of the changes in levels of CD8+ cells/µL among HIV+ participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.02","pValueComment":"The reported p-value is representative of the changes in levels of CD8+ cells/µL among HIV+ participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.36","pValueComment":"The reported p-value is representative of the changes in levels of CD8+ cells/µL among HIV+ participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG000"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.002","pValueComment":"The reported p-value is representative of the changes in levels of CD19+ cells/µL among all participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG001"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"0.0002","pValueComment":"The reported p-value is representative of the changes in levels of CD19+ cells/µL among all participants.","statisticalMethod":"Wilcoxon signed rank test"},{"groupIds":["OG002"],"nonInferiorityComment":"P\\<0.005 was considered statistically significant while 0.005 \\<P\\<0.05 was considered evidence of a strong trend.","nonInferiorityType":"OTHER","pValue":"<0.0001","pValueComment":"The reported p-value is representative of the changes in levels of CD19+ cells/µL among all participants.","statisticalMethod":"Wilcoxon signed rank test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-77.5","upperLimit":"221","value":"66.5"},{"groupId":"OG001","lowerLimit":"-57.0","upperLimit":"176.0","value":"37"},{"groupId":"OG002","lowerLimit":"-178.5","upperLimit":"91.5","value":"-54"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"title":"CD4+/All participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-29","upperLimit":"257","value":"72"},{"groupId":"OG001","lowerLimit":"-15","upperLimit":"291","value":"37"},{"groupId":"OG002","lowerLimit":"-79","upperLimit":"132","value":"-14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"title":"CD4+ among HIV+ participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-76.5","upperLimit":"257","value":"104.5"},{"groupId":"OG001","lowerLimit":"-19","upperLimit":"288","value":"115"},{"groupId":"OG002","lowerLimit":"-38.5","upperLimit":"194.5","value":"73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"title":"CD8+/All participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-20","upperLimit":"414","value":"198"},{"groupId":"OG001","lowerLimit":"1","upperLimit":"430","value":"129"},{"groupId":"OG002","lowerLimit":"-102","upperLimit":"295","value":"75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"18"}],"units":"Participants"}],"title":"CD8+ among HIV+ participants"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-73","upperLimit":"-3.5","value":"-40"},{"groupId":"OG001","lowerLimit":"-123","upperLimit":"5","value":"-55"},{"groupId":"OG002","lowerLimit":"-124.5","upperLimit":"-49.5","value":"-75"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"title":"CD19+/All participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"description":"Fluorescence activated cell sorting.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Baseline to 4 weeks for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days. Includes 18 HIV+ participants.","id":"OG000","title":"Baseline to 4 Weeks"},{"description":"Baseline to 8 weeks for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days. Includes 18 HIV+ participants.","id":"OG001","title":"Baseline to 8 Weeks"},{"description":"Baseline to end of treatment for participants treated with pomalidomide 5 mg by mouth (p.o.) for 21 of 28 days. Includes 18 HIV+ participants.","id":"OG002","title":"Baseline to End of Treatment"}],"paramType":"MEDIAN","populationDescription":"HIV+ participants = 18.","reportingStatus":"POSTED","timeFrame":"Baseline to 4 weeks, baseline to 8 weeks, and baseline to end of treatment","title":"Change in Immune Cytokines Cluster of Differentiation 4 (CD4), Cluster of Differentiation 8 (CD8) and Cluster of Differentiation 19 (CD19) Among Participants With and/or Without Human Immunodeficiency Virus (HIV)","type":"SECONDARY","unitOfMeasure":"cells/µL"}